Please login to the form below
Janssen
This page shows the latest Janssen news and features for those working in and with pharma, biotech and healthcare.
Janssen reports positive real-world data for Tremfya in psoriatic arthritis
Janssen Pharmaceuticals, a Johnson &Johnson company, has announced positive real-world data for its IL-23 inhibitor Tremfya (guselkumab) in adults with treatment-resistant active psoriatic arthritis (PsA). ... in pain, physical function and fatigue
Latest news
-
Janssen reveals positive results for nipocalimab in rheumatoid arthritis
Janssen, a Johnson &Johnson company, has announced positive results from a mid-stage study of its investigational FcRn inhibitor in rheumatoid arthritis (RA). ... Terence Rooney, vice president and rheumatology disease area leader at Janssen, said:
-
Amgen’s Wezlana receives FDA approval to treat multiple inflammatory diseases
Wezlana is now approved as a biosimilar to and interchangeable with Janssen Pharmaceuticals’ Stelara (ustekinumab). ... Most recently, Janssen’s Stelara received FDA approval for the treatment of paediatric patients aged six years and older with
-
GSK to acquire exclusive rights to Janssen’s hepatitis B therapy in $1bn deal
GSK and Arrowhead Pharmaceuticals have announced that they have reached an agreement with Janssen Pharmaceuticals to receive exclusive rights to its hepatitis B therapy, JNJ-3989. ... The Johnson &Johnson company’s investigational hepatitis B virus (HBV
-
Sanofi partners with AI specialist BioMap in deal worth more than $1bn
The company also signed a deal with Janssen Pharmaceuticals, now Johnson &Johnson Innovative Medicine, to develop and commercialise an experimental vaccine candidate developed by the Johnson &Johnson unit for extraintestinal pathogenic
-
Nanobiotix shares promising results for radiotherapy enhancer in advanced pancreatic cancer
The positive readout comes just a few months after Nanobiotix gave Janssen Pharmaceuticals – now Johnson &Johnson Innovative Medicine – a worldwide licence for the development and commercialisation of NBTXR3, except in territories
More from news
Approximately 177 fully matching, plus 427 partially matching documents found.
Latest Intelligence
-
Pharma AI: how sales and marketing are starting to step out of R&D’s shadow
More recently, Janssen saw streamlining opportunities for its content review process with the AI-powered Smart Reviewer system, which picks up language or factual errors and flags information that needs to
-
The rise of biologics: is the sector ready for future demand?
Today, leading biologics manufacturers such as Pfizer, BMS, Janssen, Amgen, Sanofi, Takeda, including leading emerging names like MeiraGTx, Horizon, Alexion, BioMarin, have their tech ops and manufacturing sites (bulk drug,
-
Tuberculosis – why it remains a major global public health challenge
In August 2022, four partners from the PAN-TB collaboration – Janssen Pharmaceutica NV, Otsuka, TB Alliance and Gates MRI – executed a joint development agreement (JDA) supporting the progression of two investigational ... 1. Bedaquiline – a
-
The importance of value when treating patients
Jennifer Lee is Therapy Area Market Access Leader for Janssen EMEA.
-
Customers, content and change
Personalisation was also cited as one of three key trends shaping the future of our industry, along with commercial excellence and flexibility, by Janssen’s Maria Raad, Janssen EMEA’s vice
More from intelligence
Approximately 5 fully matching, plus 62 partially matching documents found.
Latest appointments
-
Genmab appoints Tahamtan Ahmadi as chief medical officer, head of experimental medicines
Prior to Genmab, Ahmadi worked as head of experimental medicine and early development oncology at Janssen.
-
Ex-J&J exec Denice Torres joins bluebird bio’s board
During her time at J&J, Torres held several executive leadership roles including president of McNeil Consumer Healthcare and president of Janssen Pharmaceuticals, CNS.
-
New hires at Bristol-Myers Squibb, Acceleron and FerGene
He has also served in various executive leadership roles at Novartis Pharma and Novartis Oncology, and he began his career at Johnson &Johnson and Janssen.
-
Robert Freisen joins Ablynx
He has previously held roles for ProQR Therapeutics, Janssen BioTherapeutics, and MorphoSys.
-
Mundipharma appoints Dr Alberto Martinez as president and CEO
Prior to his time at Mundipharma, he served Napp Pharmaceuticals and Janssen in various capacities.
More from appointments
Approximately 3 fully matching, plus 27 partially matching documents found.
Latest from PMHub
-
FREE WEBINAR: End-to-end patient strategy: making a treatment for patients, with patients
Our first confirmed speaker is Daniel de Schryver, Patient Engagement &Advocacy Lead, Europe, Middle-East and Africa, Janssen.
-
VISFO invests in a new brand as it continues to grow its client base in the US and Europe
Working with global pharma clients such as Takeda, GSK, Janssen and Abbvie, the consultancy is on a trajectory for growth and has doubled in size due to its commitment to technology,
-
What does the future hold for Light-chain Amyloidosis?
Recently, Darzalex (daratumumab), a monoclonal antibody developed by Genmab and Janssen, that has been available for the management of patients with multiple myeloma across Europe for 5 years, was granted accelerated
-
OPEN Health’s Learning & Development team have won a Bronze Award at the PM Society Digital Awards 2020
READ MORE ABOUT OUR WINNING PROJECT WITH WITH JANSSEN BELOW:. The Immunology Training Summit (ITS) 2020 with the Janssen EMEA Immunology team took a week-long face-to-face meeting for ... Strikingly this format is now considered best practice in
-
Mednet Group
Clinigen. Crohns and Colitis Department for International Development. Eisai. Gilead. Janssen.
More from PMHub
Approximately 5 fully matching, plus 28 partially matching documents found.
Subscribe to our email news alerts
- New Playbook Alert: Virtual Patient Engagement
- AbbVie to expand solid tumour portfolio with $10bn ImmunoGen acquisition
- UK Biobank reveals new data from world's largest genetic project
- New study finds dose of Mavenclad treatment could predict MS relapse risk
- Astellas shares positive 24-week results for non-hormonal menopause drug fezolinetant
- GSK global survey reveals misunderstandings about shingles in adults
No results were found
PMHub
Lucid Group Communications Limited
WE’RE ON A MISSION
To transform lives through communication that changes behaviour and improves health outcomes....
Latest intelligence
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
